EFFECTIVENESS OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY
DOI:
https://doi.org/10.51253/pafmj.v65iSUPPL-2.12518Keywords:
Bevacizumab, Diabetic Retinopathy, Neovascularisation, Proliferative, Vascular Endothelial Growth Factor.Abstract
Objective: To assess the effectiveness of intravitreal injection of bevacizumab (Avastin) in the treatment of
proliferative diabetic retinopathy.
Study Design: Quasi experimental study.
Place and Duration of Study: This study was conducted at the department of ophthalmology, Jinnah post
graduate medical centre, Karachi from 26th January 2011 to 26th January 2012.
Material and Methods: The study group comprised of 55 eyes of proliferative diabetic retinopathy (PDR).
Pre procedure fundus fluorescein angiography (FFA) was done in all patients. Intravitreal injection of 1.25
mg of bevacizumab (avastin) was injected 3.5 mm from the limbus under topical anesthetic drops. Post
procedure follow up was scheduled on 1st post procedure day, two weeks and after one month. Post
procedure FFA was performed on all patients at 1st month after 1st injection. Results were entered and
analyzed using SPSS Version 17.
Results: Out of the 55 eyes of 41 patients who were given the intravitreal injection of avastin
(bevacizumab), 42 eyes (72.17%) showed complete regression of neovascularisation, 12 eyes (21.8%) had
partial regression and 3 eyes (5.5%) revealed no response.
Conclusion: Intravitreal injection of bevacizumab (avastin) is effective in regressing the retinal
neovascularisation in controlled and uncontrolled diabetics of insulin-dependent diabetes mellitus (IDDM)
and non-insulin-dependent diabetes mellitus (NIDDM) patients.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2015 Muhammad Ali Tahir, Alyscia M Cheema, Quratulain Saleem, Arif Rabani Diari, Saifullah Tareen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.